Protection of Liver function with Protease Inhibitor from Ischemia-Reperfusion Injury in Hepatocellular Carcinoma Patients Undergoing Hepatectomy after Hepatic Inflow Occlusion
- VernacularTitle:蛋白酶抑制剂对肝癌患者入肝血流阻断肝切除术后肝功能的保护作用
- Author:
Shaoqiang LI
;
Lijian LIANG
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma Ischemia Injury Liver function Protease inhibitor Ulinastatin
- From:
Chinese Journal of Bases and Clinics in General Surgery
2004;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate whether protease inhibitor (ulinastatin, UTI) can protect liver from ischemia-reperfusion injury in hepatocellular carcinoma (HCC) patients undergoing hepatectomy after hepatic inflow occlusion. Methods A prospective randomized control study was designed. Thirty-one HCC patients undergoing hepatectomy after hepatic inflow blood occlusion were randomly divided into the following two groups. UTI group (n=16), 1?105 units of ulinastatin was given intravenously in operation, then the dosage was continuously used twice a day up to 5 days postoperatively. Control group (n=15), the patients received other liver protective drugs. Liver function, plasma C-reactive protein (CRP) and cortisol level were compared between these two groups. Results The postoperative liver function of the UTI group was significantly improved compared with the control group. For example, on the third postoperative day the aspartate transaminase (AST), alanine transaminase (ALT) and total bilirubin level in the UTI group were significantly lower than those in the control group, respectively (P
